Altimmune, Inc.

4.0000-0.06 (-1.48%)

Oct 29, 4:00:01 PM EDT · NasdaqGM · ALT · USD

Upcoming Earnings

Report date

Nov 11, 2025 (in 12 days)

Key Stats

Market Cap

353.03M

P/E (TTM)

Basic EPS (TTM)

-1.18

Dividend Yield

Recent Filings

8-K

10/3/25Oct 3, 2025

8-K

9/25/25Sep 25, 2025

8-K

8/12/25Aug 12, 2025

10-Q

8/12/25Aug 12, 2025

8-K

6/26/25Jun 26, 2025

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

CEO

Dr. Vipin K. Garg Ph.D.

IPO

5/26/2017

Website

https://altimmune.com

Employees

Sector

Healthcare

Industry

Biotechnology